FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Miki Nakajima

Research Profile

Chemicals & Drugs

Anatomy

Co-author Network

Publications

TOP 3
Ryota Higuchi; Miki Nakajima; Tatsuki Fukami; Tsuyoshi Yokoi
Prilocaine- and Lidocaine-Induced Methemoglobinemia Is Caused by Human Carboxylesterase-, CYP2E1-, and CYP3A4-Mediated Metabolic Activation.
Tsuyoshi Yokoi; Miki Nakajima
microRNAs as mediators of drug toxicity.
Yuki Kobayashi; Miki Nakajima; Tatsuki Fukami; Ryota Higuchi; Tsuyoshi Yokoi
Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Miki Nakajima (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ryota Higuchi; Miki Nakajima; Tatsuki Fukami; Tsuyoshi Yokoi
Prilocaine- and Lidocaine-Induced Methemoglobinemia Is Caused by Human Carboxylesterase-, CYP2E1-, and CYP3A4-Mediated Metabolic Activation.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(6):1220-30.
2013: Tsuyoshi Yokoi; Miki Nakajima
microRNAs as mediators of drug toxicity.
Annual review of pharmacology and toxicology 2013;53():377-400.
2012: Yuki Kobayashi; Miki Nakajima; Tatsuki Fukami; Ryota Higuchi; Tsuyoshi Yokoi
Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia.
Biochemical pharmacology 2012;84(9):1196-206.
2012: Satonori Higuchi; Miki Nakajima; Shohei Takai; Koichi tsuneyama; Azusa Yano; Tatsuki Fukami; Tsuyoshi Yokoi
Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury.
Toxicological sciences : an official journal of the Society of Toxicology 2012;130(1):4-16.
2012: Yukitaka Yoshikawa; Shinya Endo; Tatsuki Fukami; Satonori Higuchi; Taishi Miyashita; Miki Nakajima; Yasuyuki Toyoda; Tohru Tsukui; Koichi tsuneyama; Tsuyoshi Yokoi
Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries.
Toxicology and applied pharmacology 2012;264(1):42-50.
2012: Masanori Kobayashi; Miki Nakajima; Satomi Nishikawa; Tatsuki Fukami; Satonori Higuchi; Mika Ide; Tsuyoshi Yokoi
Th2 cytokine-mediated methimazole-induced acute liver injury in mice.
Journal of applied toxicology : JAT 2012;32(10):823-33.
2012: Satonori Higuchi; Masanori Kobayashi; Miki Nakajima; Koichi tsuneyama; Azusa Yano; Tatsuki Fukami; Tsuyoshi Yokoi
Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury.
Journal of applied toxicology : JAT 2012;32(10):815-22.
2012: Shingo Oda; Tatsuki Fukami; Masahiko Hatakeyama; Miki Nakajima; Tsuyoshi Yokoi
Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(8):1620-7.
2012: Yuki Kobayashi; Miki Nakajima; Mai Shimizu; Tatsuki Fukami; Tsuyoshi Yokoi
Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(6):1080-4.
2012: Mai Shimizu; Masataka Takamiya; Yasuhiro Aoki; Tatsuki Fukami; Yuki Kobayashi; Miki Nakajima; Tsuyoshi Yokoi
A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(6):1183-90.
2012: Yuki Oda; Masataka Takamiya; Yasuhiro Aoki; Tatsuki Fukami; Takuya Mohri; Miki Nakajima; Tsuyoshi Yokoi
Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24.
Toxicology and applied pharmacology 2012;260(3):222-31.
2012: Yuki Kobayashi; Akinori Nakajima; Miki Nakajima; Akinobu Watanabe; Tatsuki Fukami; Tsuyoshi Yokoi
Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(4):671-9.
2012: Atsushi Iwamura; Miki Nakajima; Tatsuki Fukami; Ryota Higuchi; Tsuyoshi Yokoi
Human α/β hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver.
The Journal of biological chemistry 2012;287(12):9240-9.
2012: Azusa Yano; Tatsuki Fukami; Satonori Higuchi; Miki Nakajima; Koichi tsuneyama; Tsuyoshi Yokoi
Involvement of immune-related factors in diclofenac-induced acute liver injury in mice.
Toxicology 2012;293(1-3):107-14.
2012: Yasuyuki Toyoda; Koichi tsuneyama; Azusa Yano; Shinya Endo; Tatsuki Fukami; Taishi Miyashita; Miki Nakajima; Tsuyoshi Yokoi
Mechanism of exacerbative effect of progesterone on drug-induced liver injury.
Toxicological sciences : an official journal of the Society of Toxicology 2012;126(1):16-27.
2012: Yukiko Kato; Miki Nakajima; Shingo Oda; Tatsuki Fukami; Tsuyoshi Yokoi
Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(2):240-8.
2012: Taishi Miyashita; Miki Nakajima; Yasuyuki Toyoda; Koichi tsuneyama; Tatsuki Fukami; Tsuyoshi Yokoi
Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models.
The Journal of toxicological sciences 2012;37(5):931-42.
2012: Shinya Endo; Tatsuki Fukami; Miki Nakajima; Yasuyuki Toyoda; Tsuyoshi Yokoi
Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs.
Drug metabolism and pharmacokinetics 2012;27(6):621-30.
2012: Yu Yamaura; Tatsuki Fukami; Miki Nakajima; Shingo Takagi; Koichi tsuneyama; Tsuyoshi Yokoi
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
PloS one 2012;7(2):e30250.
2011: Akinori Nakajima; Miki Nakajima; Akinobu Watanabe; Tatsuki Fukami; Yuki Kobayashi; Tsuyoshi Yokoi
Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine.
Biochemical pharmacology 2011;82(11):1747-56.
2011: Shingo Oda; Yasuyuki Toyoda; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(11):2057-65.
2011: Katsuhiko Kida; Takuya Mohri; Miki Nakajima; Yuki Oda; Shingo Takagi; Tatsuki Fukami; Tsuyoshi Yokoi
PPARα is regulated by miR-21 and miR-27b in human liver.
Pharmaceutical research 2011;28(10):2467-76.
2011: Tsuyoshi Yokoi; Miki Nakajima
Toxicological implications of modulation of gene expression by microRNAs.
Toxicological sciences : an official journal of the Society of Toxicology 2011;123(1):1-14.
2011: Hiroko Hosomi; Atsushi Iwamura; Miki Nakajima; Tatsuki Fukami; Tsuyoshi Yokoi
Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(8):1388-95.
2011: Tomomi Hioki; Miki Nakajima; Tatsuki Fukami; Tsuyoshi Yokoi
Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(8):1345-52.
2011: Yasuyuki Toyoda; Taishi Miyashita; Shinya Endo; Koichi tsuneyama; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
Estradiol and progesterone modulate halothane-induced liver injury in mice.
Toxicology letters 2011;204(1):17-24.
2011: Yuko Abe; Ryoichi Fujiwara; Shingo Oda; Tsuyoshi Yokoi; Miki Nakajima
Interpretation of the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo.
Drug metabolism and pharmacokinetics 2011;26(3):256-65.
2011: Atsushi Iwamura; Tatsuki Fukami; Hiroko Hosomi; Miki Nakajima; Tsuyoshi Yokoi
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(5):838-46.
2011: Katsuhiko Mizuno; Yasuyuki Toyoda; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway.
Archives of toxicology 2011;85(3):199-207.
2011: Satonori Higuchi; Masanori Kobayashi; Yukitaka Yoshikawa; Koichi tsuneyama; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
IL-4 mediates dicloxacillin-induced liver injury in mice.
Toxicology letters 2011;200(3):139-45.
2011: Shin-Ichi Yokota; Eriko Higashi; Tatsuki Fukami; Tsuyoshi Yokoi; Miki Nakajima
Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2.
Biochemical pharmacology 2011;81(2):289-94.
2011: Toshihisa Koga; Ryoichi Fujiwara; Miki Nakajima; Tsuyoshi Yokoi
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(1):54-60.
2010: Tatsuki Fukami; Shiori Takahashi; Nao Nakagawa; Taiga Maruichi; Miki Nakajima; Tsuyoshi Yokoi
In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities.
Drug metabolism and disposition: the biological fate of chemicals 2010;38(12):2173-8.
2010: Masanori Kobayashi; Satonori Higuchi; Katsuhiko Mizuno; Koichi tsuneyama; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice.
Toxicology 2010;275(1-3):50-7.
2010: Akinobu Watanabe; Tatsuki Fukami; Shiori Takahashi; Yuki Kobayashi; Nao Nakagawa; Miki Nakajima; Tsuyoshi Yokoi
Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen.
Drug metabolism and disposition: the biological fate of chemicals 2010;38(9):1532-7.
2010: Miki Nakajima; Toshihisa Koga; Haruko Sakai; Hiroyuki Yamanaka; Ryoichi Fujiwara; Tsuyoshi Yokoi
N-Glycosylation plays a role in protein folding of human UGT1A9.
Biochemical pharmacology 2010;79(8):1165-72.
2010: Tatsuki Fukami; Miki Nakajima; Isao Matsumoto; Yoh Zen; Makoto Oda; Tsuyoshi Yokoi
Immunohistochemical analysis of CYP2A13 in various types of human lung cancers.
Cancer science 2010;101(4):1024-8.
2010: Hiroko Hosomi; Sho Akai; Keiichi Minami; Yukitaka Yoshikawa; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells.
Toxicology in vitro : an international journal published in association with BIBRA 2010;24(3):1032-8.
2010: Takuya Mohri; Miki Nakajima; Tatsuki Fukami; Masataka Takamiya; Yasuhiro Aoki; Tsuyoshi Yokoi
Human CYP2E1 is regulated by miR-378.
Biochemical pharmacology 2010;79(7):1045-52.
2010: Shingo Takagi; Miki Nakajima; Katsuhiko Kida; Yu Yamaura; Tatsuki Fukami; Tsuyoshi Yokoi
MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle.
The Journal of biological chemistry 2010;285(7):4415-22.
2010: Taiga Maruichi; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2).
Biochemical pharmacology 2010;79(2):288-95.
2010: Ryoichi Fujiwara; Miki Nakajima; Shingo Oda; Hiroyuki Yamanaka; Shin-ichi Ikushiro; Toshiyuki Sakaki; Tsuyoshi Yokoi
Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes.
Journal of pharmaceutical sciences 2010;99(1):442-54.
2009: Yukitaka Yoshikawa; Mayu Morita; Hiroko Hosomi; Koichi tsuneyama; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat.
Toxicology 2009;264(1-2):89-95.
2009: Eisuke Kobayashi; Masanori Kobayashi; Koichi tsuneyama; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
Halothane-induced liver injury is mediated by interleukin-17 in mice.
Toxicological sciences : an official journal of the Society of Toxicology 2009;111(2):302-10.
2009: Sayaka Komagata; Miki Nakajima; Shingo Takagi; Takuya Mohri; Takao Taniya; Tsuyoshi Yokoi
Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b.
Molecular pharmacology 2009;76(4):702-9.
2009: Takuya Mohri; Miki Nakajima; Shingo Takagi; Sayaka Komagata; Tsuyoshi Yokoi
MicroRNA regulates human vitamin D receptor.
International journal of cancer. Journal international du cancer 2009;125(6):1328-33.
2009: Mayu Morita; Sho Akai; Hiroko Hosomi; Koichi tsuneyama; Miki Nakajima; Tsuyoshi Yokoi
Drug-induced hepatotoxicity test using gamma-glutamylcysteine synthetase knockdown rat.
Toxicology letters 2009;189(2):159-65.
2009: Yukitaka Yoshikawa; Hiroko Hosomi; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi
Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity.
Toxicology in vitro : an international journal published in association with BIBRA 2009;23(6):1179-87.
2009: Takeshi Izukawa; Miki Nakajima; Ryoichi Fujiwara; Hiroyuki Yamanaka; Tatsuki Fukami; Masataka Takamiya; Yasuhiro Aoki; Shin-ichi Ikushiro; Toshiyuki Sakaki; Tsuyoshi Yokoi
Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(8):1759-68.
2009: Akinobu Watanabe; Tatsuki Fukami; Miki Nakajima; Masataka Takamiya; Yasuhiro Aoki; Tsuyoshi Yokoi
Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(7):1513-20.
2009: Shiori Takahashi; Miki Katoh; Takashi Saitoh; Miki Nakajima; Tsuyoshi Yokoi
Different inhibitory effects in rat and human carboxylesterases.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(5):956-61.
2009: Katsuhiko Mizuno; Miki Katoh; Hirotoshi Okumura; Nao Nakagawa; Toru Negishi; Takanori Hashizume; Miki Nakajima; Tsuyoshi Yokoi
Metabolic activation of benzodiazepines by CYP3A4.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(2):345-51.
2009: Nao Nakagawa; Miki Katoh; Yuko Yoshioka; Miki Nakajima; Tsuyoshi Yokoi
Inhibitory effects of Kampo medicine on human UGT2B7 activity.
Drug metabolism and pharmacokinetics 2009;24(6):490-9.
2009: Ryoichi Fujiwara; Miki Nakajima; Tetsunori Yamamoto; Hidemi Nagao; Tsuyoshi Yokoi
In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9.
Drug metabolism and pharmacokinetics 2009;24(3):235-44.
2008: Shiori Takahashi; Miki Katoh; Takashi Saitoh; Miki Nakajima; Tsuyoshi Yokoi
Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability.
Journal of pharmaceutical sciences 2008;97(12):5434-45.
2008: Keiichi Minami; Miki Nakajima; Yuto Fujiki; Miki Katoh; Frank J Gonzalez; Tsuyoshi Yokoi
Regulation of insulin-like growth factor binding protein-1 and lipoprotein lipase by the aryl hydrocarbon receptor.
The Journal of toxicological sciences 2008;33(4):405-13.
2008: Tatsuki Fukami; Miki Nakajima; Taiga Maruichi; Shiori Takahashi; Masataka Takamiya; Yasuhiro Aoki; howard mcleod; Tsuyoshi Yokoi
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes.
Pharmacogenetics and genomics 2008;18(10):911-20.
2008: Hirotada Shiratani; Miki Katoh; Miki Nakajima; Tsuyoshi Yokoi
Species differences in UDP-glucuronosyltransferase activities in mice and rats.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(9):1745-52.
2008: Akiko Nakamura; Miki Nakajima; Eriko Higashi; Hiroyuki Yamanaka; Tsuyoshi Yokoi
Genetic polymorphisms in the 5'-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation.
Pharmacogenetics and genomics 2008;18(8):709-20.
2008: Akiko Nakamura; Miki Nakajima; Hiroyuki Yamanaka; Ryoichi Fujiwara; Tsuyoshi Yokoi
Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(8):1461-4.
2008: Shingo Takagi; Miki Nakajima; Takuya Mohri; Tsuyoshi Yokoi
Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4.
The Journal of biological chemistry 2008;283(15):9674-80.
2008: Tatsuki Fukami; Miki Katoh; Hiroshi Yamazaki; Tsuyoshi Yokoi; Miki Nakajima
Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene.
Chemical research in toxicology 2008;21(3):720-5.
2008: Ryoichi Fujiwara; Miki Nakajima; Hiroyuki Yamanaka; Miki Katoh; Tsuyoshi Yokoi
Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(2):361-7.
2007: Miki Nakajima
Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.
Current opinion in molecular therapeutics 2007;9(6):538-44.
2007: Eriko Higashi; Tatsuki Fukami; Masahiro Itoh; Satoru Kyo; Masaki Inoue; Tsuyoshi Yokoi; Miki Nakajima
Human CYP2A6 is induced by estrogen via estrogen receptor.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(10):1935-41.
2007: Ryoichi Fujiwara; Miki Nakajima; Hiroyuki Yamanaka; Miki Katoh; Tsuyoshi Yokoi
Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(10):1781-7.
2007: Hiroyuki Yamanaka; Miki Nakajima; Miki Katoh; Tsuyoshi Yokoi
Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(9):1642-8.
2007: Miki Nakajima; Hiroyuki Yamanaka; Ryoichi Fujiwara; Miki Katoh; Tsuyoshi Yokoi
Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(9):1679-86.
2007: Sho Akai; Hiroko Hosomi; Keiichi Minami; Koichi tsuneyama; Miki Katoh; Miki Nakajima; Tsuyoshi Yokoi
Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity.
The Journal of biological chemistry 2007;282(33):23996-4003.
2007: Hirotoshi Okumura; Miki Katoh; Keiichi Minami; Miki Nakajima; Tsuyoshi Yokoi
Change of drug excretory pathway by CCl4-induced liver dysfunction in rat.
Biochemical pharmacology 2007;74(3):488-95.
2007: Miki Nakajima; Sayaka Komagata; Yuto Fujiki; Yoshihiro Kanada; Hiromichi Ebi; Kuniaki Itoh; Hirofumi Mukai; Tsuyoshi Yokoi; Hironobu Minami
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Pharmacogenetics and genomics 2007;17(6):431-45.
2007: Hirotoshi Okumura; Miki Katoh; Toshiro Sawada; Miki Nakajima; Yoshinori Soeno; Hikaru Yabuuchi; Toshihiko Ikeda; Chise Tateno; Katsutoshi Yoshizato; Tsuyoshi Yokoi
Humanization of excretory pathway in chimeric mice with humanized liver.
Toxicological sciences : an official journal of the Society of Toxicology 2007;97(2):533-8.
2007: Ryoichi Fujiwara; Miki Nakajima; Hiroyuki Yamanaka; Akiko Nakamura; Miki Katoh; Shin-ichi Ikushiro; Toshiyuki Sakaki; Tsuyoshi Yokoi
Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(5):747-57.
2007: Yusuke Hara; Miki Nakajima; Ken-ichi Miyamoto; Tsuyoshi Yokoi
Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine.
Drug metabolism and pharmacokinetics 2007;22(2):103-12.
2007: Tatsuki Fukami; Miki Nakajima; Hiroyuki Yamanaka; Yasunari Fukushima; howard mcleod; Tsuyoshi Yokoi
A novel duplication type of CYP2A6 gene in African-American population.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(4):515-20.
2007: Eriko Higashi; Miki Nakajima; Miki Katoh; Shogo Tokudome; Tsuyoshi Yokoi
Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(4):508-14.
2007: Tatsuki Fukami; Miki Nakajima; Haruko Sakai; Miki Katoh; Tsuyoshi Yokoi
CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(3):335-9.
2007: Miki Katoh; Toshiro Sawada; Yoshinori Soeno; Miki Nakajima; Chise Tateno; Katsutoshi Yoshizato; Tsuyoshi Yokoi
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.
Journal of pharmaceutical sciences 2007;96(2):428-37.
2006: Miki Nakajima; Masahiro Itoh; Haruko Sakai; Tatsuki Fukami; Miki Katoh; Hiroshi Yamazaki; Fred F Kadlubar; Susumu Imaoka; Yoshihiko Funae; Tsuyoshi Yokoi
CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl.
International journal of cancer. Journal international du cancer 2006;119(11):2520-6.
2006: Masahiro Itoh; Miki Nakajima; Eriko Higashi; Ryoko Yoshida; Kiyoshi Nagata; Yasushi Yamazoe; Tsuyoshi Yokoi
Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha.
The Journal of pharmacology and experimental therapeutics 2006;319(2):693-702.
2006: Rawiwan Maniratanachote; Keiichi Minami; Miki Katoh; Miki Nakajima; Tsuyoshi Yokoi
Dephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicity.
Toxicology letters 2006;166(3):189-99.
2006: Yuki Tsuchiya; Miki Nakajima; Shingo Takagi; Takao Taniya; Tsuyoshi Yokoi
MicroRNA regulates the expression of human cytochrome P450 1B1.
Cancer research 2006;66(18):9090-8.
2006: Miki Nakajima; Tatsuki Fukami; Hiroyuki Yamanaka; Eriko Higashi; Haruko Sakai; Ryoko Yoshida; Jun-Tack Kwon; howard mcleod; Tsuyoshi Yokoi
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Clinical pharmacology and therapeutics 2006;80(3):282-97.
2006: Sayaka Komagata; Miki Nakajima; Yuki Tsuchiya; Miki Katoh; Ryoichi Kizu; Satoru Kyo; Tsuyoshi Yokoi
Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens.
The Journal of steroid biochemistry and molecular biology 2006;100(1-3):79-86.
2006: Yuki Tsuchiya; Miki Nakajima; Shingo Takagi; Miki Katoh; Wenchao Zheng; Colin R Jefcoate; Tsuyoshi Yokoi
Binding of steroidogenic factor-1 to the regulatory region might not be critical for transcriptional regulation of the human CYP1B1 gene.
Journal of biochemistry 2006;139(3):527-34.
2006: Miki Nakajima; Masahiro Itoh; Hiroyuki Yamanaka; Tatsuki Fukami; Shogo Tokudome; Yasuhiko Yamamoto; Hiroshi Yamamoto; Tsuyoshi Yokoi
Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6.
Journal of clinical pharmacology 2006;46(3):337-44.
2006: Keiichi Minami; Rawiwan Maniratanachote; Miki Katoh; Miki Nakajima; Tsuyoshi Yokoi
Simultaneous measurement of gene expression for hepatotoxicity in thioacetamide-administered rats by DNA microarrays.
Mutation research 2006;603(1):64-73.
2005: Hiroyuki Yamanaka; Miki Nakajima; Tatsuki Fukami; Haruko Sakai; Akiko Nakamura; Miki Katoh; Masataka Takamiya; Yasuhiro Aoki; Tsuyoshi Yokoi
CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(12):1811-8.
2005: Rawiwan Maniratanachote; Ayaka Shibata; Shuichi Kaneko; Ikuo Yamamori; Takanobu Wakasugi; Takeshi Sawazaki; Kanefusa Katoh; Shogo Tokudome; Miki Nakajima; Tsuyoshi Yokoi
Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Toxicology 2005;216(1):15-23.
2005: Yuki Tsuchiya; Miki Nakajima; Tsuyoshi Yokoi
Cytochrome P450-mediated metabolism of estrogens and its regulation in human.
Cancer letters 2005;227(2):115-24.
2005: Miki Katoh; M Watanabe; T Tabata; Y Sato; Miki Nakajima; M Nishimura; S Naito; Chise Tateno; K Iwasaki; Katsutoshi Yoshizato; Tsuyoshi Yokoi
In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver.
Xenobiotica; the fate of foreign compounds in biological systems 2005;35(9):863-75.
2005: Tatsuki Fukami; Miki Nakajima; Eriko Higashi; Hiroyuki Yamanaka; howard mcleod; Tsuyoshi Yokoi
A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Biochemical pharmacology 2005;70(5):801-8.
2005: Keiichi Minami; Toshiro Saito; Masatoshi Narahara; Hiroyuki Tomita; Hirokazu Kato; Hisashi Sugiyama; Miki Katoh; Miki Nakajima; Tsuyoshi Yokoi
Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats.
Toxicological sciences : an official journal of the Society of Toxicology 2005;87(1):296-305.
2005: Miki Katoh; Tomohito Matsui; Hirotoshi Okumura; Miki Nakajima; Masuhiro Nishimura; Shinsaku Naito; Chise Tateno; Katsutoshi Yoshizato; Tsuyoshi Yokoi
Expression of human phase II enzymes in chimeric mice with humanized liver.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(9):1333-40.
2005: Miki Nakajima; Tsuyoshi Yokoi
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Drug metabolism and pharmacokinetics 2005;20(4):227-35.
2005: Tatsuki Fukami; Miki Nakajima; Eriko Higashi; Hiroyuki Yamanaka; Haruko Sakai; howard mcleod; Tsuyoshi Yokoi
Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(8):1202-10.
2005: Y Hara; Miki Nakajima; K-I Miyamoto; Tsuyoshi Yokoi
Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions.
Xenobiotica; the fate of foreign compounds in biological systems 2005;35(6):549-60.
2005: Miki Nakajima; Yuto Fujiki; Satoru Kyo; Taro Kanaya; Mitsuhiro Nakamura; Yoshiko Maida; Masaaki Tanaka; Masaki Inoue; Tsuyoshi Yokoi
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
Journal of clinical pharmacology 2005;45(6):674-82.
2005: Miki Katoh; Tomohito Matsui; Miki Nakajima; Chise Tateno; Yoshinori Soeno; Toru Horie; Kazuhide Iwasaki; Katsutoshi Yoshizato; Tsuyoshi Yokoi
In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(6):754-63.
2005: Hiroyuki Yamanaka; Miki Nakajima; Yusuke Hara; Miki Katoh; Osamu Tachibana; Junkoh Yamashita; Tsuyoshi Yokoi
Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases.
Drug metabolism and pharmacokinetics 2005;20(2):135-43.
2005: Miki Nakajima; Tsuyoshi Yokoi
Cancer pharmacogenomics: achievements in basic research.
International journal of clinical oncology 2005;10(1):14-9.
2005: Rawiwan Maniratanachote; Keiichi Minami; Miki Katoh; Miki Nakajima; Tsuyoshi Yokoi
Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.
Toxicological sciences : an official journal of the Society of Toxicology 2005;83(2):293-302.
2005: Hiroyuki Yamanaka; Miki Nakajima; Miki Katoh; Ayano Kanoh; Osamu Tamura; Hiroyuki Ishibashi; Tsuyoshi Yokoi
Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(1):23-30.
2004: Tatsuki Fukami; Miki Nakajima; Ryoko Yoshida; Yuki Tsuchiya; Yuto Fujiki; Miki Katoh; howard mcleod; Tsuyoshi Yokoi
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Clinical pharmacology and therapeutics 2004;76(6):519-27.
2004: Miki Katoh; Tomohito Matsui; Miki Nakajima; Chise Tateno; Miho Kataoka; Yoshinori Soeno; Toru Horie; Kazuhide Iwasaki; Katsutoshi Yoshizato; Tsuyoshi Yokoi
Expression of human cytochromes P450 in chimeric mice with humanized liver.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(12):1402-10.
2004: Toshiki Tabata; Miki Katoh; Shogo Tokudome; Miki Nakajima; Tsuyoshi Yokoi
Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(10):1103-10.
2004: Hiroyuki Yamanaka; Miki Nakajima; Kiyoko Nishimura; Ryoko Yoshida; Tatsuki Fukami; Miki Katoh; Tsuyoshi Yokoi
Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2004;22(5):419-25.
2004: Miki Nakajima; Ryoko Yoshida; Tatsuki Fukami; howard mcleod; Tsuyoshi Yokoi
Novel human CYP2A6 alleles confound gene deletion analysis.
FEBS letters 2004;569(1-3):75-81.
2004: Toshiki Tabata; Miki Katoh; Shogo Tokudome; Masakiyo Hosakawa; Kan Chiba; Miki Nakajima; Tsuyoshi Yokoi
Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(7):762-7.
2004: Kei Takemoto; Miki Nakajima; Yuto Fujiki; Miki Katoh; Frank J Gonzalez; Tsuyoshi Yokoi
Role of the aryl hydrocarbon receptor and Cyp1b1 in the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Archives of toxicology 2004;78(6):309-15.
2004: Yuki Tsuchiya; Miki Nakajima; Satoru Kyo; Taro Kanaya; Masaki Inoue; Tsuyoshi Yokoi
Human CYP1B1 is regulated by estradiol via estrogen receptor.
Cancer research 2004;64(9):3119-25.
2004: Hiroyuki Yamanaka; Miki Nakajima; Miki Katoh; Yusuke Hara; Osamu Tachibana; Junkoh Yamashita; howard mcleod; Tsuyoshi Yokoi
A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity.
Pharmacogenetics 2004;14(5):329-32.
2003: Miki Nakajima; Masashi Iwanari; Tsuyoshi Yokoi
Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells.
Toxicology letters 2003;144(2):247-56.
2003: Ryoko Yoshida; Miki Nakajima; Kiyoko Nishimura; Shogo Tokudome; Jun-Tack Kwon; Tsuyoshi Yokoi
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Clinical pharmacology and therapeutics 2003;74(1):69-76.
2003: Miki Nakajima; Yuto Fujiki; Kumiko Noda; Hiroki Ohtsuka; Hisashi Ohkuni; Satoru Kyo; Masaki Inoue; Yukio Kuroiwa; Tsuyoshi Yokoi
Genetic polymorphisms of CYP2C8 in Japanese population.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(6):687-90.
2003: Yuki Tsuchiya; Miki Nakajima; Tsuyoshi Yokoi
Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene.
Journal of biochemistry 2003;133(5):583-92.
2003: Yuichiro Watanabe; Miki Nakajima; Noriko Ohashi; Toshiyuki Kume; Tsuyoshi Yokoi
Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(5):589-95.
2003: Yuki Tsuchiya; Miki Nakajima; Satsuki Itoh; Masashi Iwanari; Tsuyoshi Yokoi
Expression of aryl hydrocarbon receptor repressor in normal human tissues and inducibility by polycyclic aromatic hydrocarbons in human tumor-derived cell lines.
Toxicological sciences : an official journal of the Society of Toxicology 2003;72(2):253-9.
2003: K Takemoto; Hiroshi Yamazaki; Y Tanaka; Miki Nakajima; Tsuyoshi Yokoi
Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes.
Xenobiotica; the fate of foreign compounds in biological systems 2003;33(1):43-55.
2002: Miki Nakajima; Eriko Tanaka; Jun-Tack Kwon; Tsuyoshi Yokoi
Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(12):1484-90.
2002: Yuichiro Watanabe; Miki Nakajima; Tsuyoshi Yokoi
Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(12):1462-9.
2002: Miki Nakajima; Yukio Kuroiwa; Tsuyoshi Yokoi
Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
Drug metabolism reviews 2002;34(4):865-77.
2002: Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
British journal of clinical pharmacology 2002;54(5):511-7.
2002: Miki Nakajima; Nozomi Sakata; Noriko Ohashi; Toshiyuki Kume; Tsuyoshi Yokoi
Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(11):1250-6.
2002: Kei Takemoto; Hiroshi Yamazaki; Miki Nakajima; Tsuyoshi Yokoi
Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay.
Mutation research 2002;519(1-2):199-204.
2002: Takashi Nozawa; Miki Nakajima; Ikumi Tamai; Kumiko Noda; Jun-ichi Nezu; Yoshimichi Sai; Akira Tsuji; Tsuyoshi Yokoi
Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis.
The Journal of pharmacology and experimental therapeutics 2002;302(2):804-13.
2002: Tomoko Komatsu; Hiroshi Yamazaki; Miki Nakajima; Tsuyoshi Yokoi
Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes.
Biochemical pharmacology 2002;63(12):2081-90.
2002: Masashi Iwanari; Miki Nakajima; Ryoichi Kizu; Kazuichi Hayakawa; Tsuyoshi Yokoi
Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences.
Archives of toxicology 2002;76(5-6):287-98.
2002: Miki Nakajima; Eriko Tanaka; Tomo Kobayashi; Noriko Ohashi; Toshiyuki Kume; Tsuyoshi Yokoi
Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):636-42.
2002: Miki Nakajima; Kazuhiro Tane; Sumika Nakamura; Noriaki Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities.
Journal of pharmaceutical sciences 2002;91(4):952-63.
2002: Hiroshi Yamazaki; Mami Nakamura; Tomoko Komatsu; Katsuhiro Ohyama; Naoya Hatanaka; Satoru Asahi; Noriaki Shimada; F Peter Guengerich; Tsutomu Shimada; Miki Nakajima; Tsuyoshi Yokoi
Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
Protein expression and purification 2002;24(3):329-37.
2002: Miki Nakajima; Jun-Tack Kwon; Eriko Tanaka; Tsuyoshi Yokoi
High-performance liquid chromatographic assay for N-glucuronidation of nicotine and cotinine in human liver microsomes.
Analytical biochemistry 2002;302(1):131-5.
2002: Yui Yamamoto; Hiroshi Yamazaki; Tomoko Ikeda; Terumi Watanabe; Haruo Iwabuchi; Miki Nakajima; Tsuyoshi Yokoi
Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(2):155-60.
2002: Hiroshi Yamazaki; Hitomi Iketaki; Ayaka Shibata; Miki Nakajima; Tsuyoshi Yokoi
Activities of cytochrome p450 enzymes in liver and kidney microsomes from systemic carnitine deficiency mice with a gene mutation of carnitine/organic cation transporter.
Drug metabolism and pharmacokinetics 2002;17(1):47-53.
2001: Yui Yamamoto; Miki Nakajima; Hiroshi Yamazaki; Tsuyoshi Yokoi
Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Life sciences 2001;70(4):471-82.
2001: Naoya Hatanaka; Hiroshi Yamazaki; Ryoichi Kizu; Kazuichi Hayakawa; Y Aoki; Masashi Iwanari; Miki Nakajima; Tsuyoshi Yokoi
Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust.
Carcinogenesis 2001;22(12):2033-8.
2001: Naoya Hatanaka; Hiroshi Yamazaki; Y Oda; F Peter Guengerich; Miki Nakajima; Tsuyoshi Yokoi
Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay.
Mutation research 2001;497(1-2):223-33.
2001: Miki Nakajima; R Yoshida; Noriaki Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(8):1110-3.
2001: Jun-Tack Kwon; Miki Nakajima; S Chai; Y K Yom; HK Kim; H Yamazaki; DR Sohn; T Yamamoto; Y Kuroiwa; Tsuyoshi Yokoi
Nicotine metabolism and CYP2A6 allele frequencies in Koreans.
Pharmacogenetics 2001;11(4):317-23.
2001: Hiroshi Yamazaki; Tomoko Komatsu; Kei Takemoto; Noriaki Shimada; Miki Nakajima; Tsuyoshi Yokoi
Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(6):794-7.
2001: C Emoto; Hiroshi Yamazaki; H Iketaki; S Yamasaki; T Satoh; R Shimizu; S Suzuki; Noriaki Shimada; Miki Nakajima; Tsuyoshi Yokoi
Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
Xenobiotica; the fate of foreign compounds in biological systems 2001;31(5):265-75.
2001: Hiroshi Yamazaki; Tomoko Komatsu; Kei Takemoto; M Saeki; Y Minami; Y Kawaguchi; Noriaki Shimada; Miki Nakajima; Tsuyoshi Yokoi
Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 1):427-34.
2001: Tomoko Komatsu; Hiroshi Yamazaki; Noriaki Shimada; S Nagayama; Y Kawaguchi; Miki Nakajima; Tsuyoshi Yokoi
Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):675-81.
2001: Miki Katoh; Miki Nakajima; Hiroshi Yamazaki; Tsuyoshi Yokoi
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2001;12(4):505-13.
2001: Miki Nakajima; Jun-Tack Kwon; N Tanaka; T Zenta; Yasuhiko Yamamoto; Hiroshi Yamamoto; H Yamazaki; T Yamamoto; Y Kuroiwa; Tsuyoshi Yokoi
Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Clinical pharmacology and therapeutics 2001;69(1):72-8.
2000: Hiroshi Yamazaki; Naoya Hatanaka; Ryoichi Kizu; Kazuichi Hayakawa; Noriaki Shimada; F Peter Guengerich; Miki Nakajima; Tsuyoshi Yokoi
Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1.
Mutation research 2000;472(1-2):129-38.
2000: Tomoko Komatsu; Hiroshi Yamazaki; Noriaki Shimada; Miki Nakajima; Tsuyoshi Yokoi
Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(12):1457-63.
2000: Tomoko Komatsu; Hiroshi Yamazaki; Satoru Asahi; E M Gillam; F Peter Guengerich; Miki Nakajima; Tsuyoshi Yokoi
Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(11):1361-8.
2000: K Ohyama; Miki Nakajima; Sumika Nakamura; Noriaki Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(11):1303-10.
2000: C Emoto; Hiroshi Yamazaki; S Yamasaki; Noriaki Shimada; Miki Nakajima; Tsuyoshi Yokoi
Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro.
Xenobiotica; the fate of foreign compounds in biological systems 2000;30(10):971-82.
2000: C Emoto; Hiroshi Yamazaki; S Yamasaki; Noriaki Shimada; Miki Nakajima; Tsuyoshi Yokoi
Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes.
Xenobiotica; the fate of foreign compounds in biological systems 2000;30(10):943-53.
2000: Miki Katoh; Miki Nakajima; Hiroshi Yamazaki; Tsuyoshi Yokoi
Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
Pharmaceutical research 2000;17(10):1189-97.
2000: Miki Nakajima; T Yamamoto; Y Kuroiwa; Tsuyoshi Yokoi
Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;742(1):211-5.
2000: K Ohyama; Miki Nakajima; M Suzuki; Noriaki Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.
British journal of clinical pharmacology 2000;49(3):244-53.
2000: Miki Katoh; Miki Nakajima; N Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
European journal of clinical pharmacology 2000;55(11-12):843-52.
2000: Miki Nakajima; S Yamagishi; Hiroshi Yamamoto; T Yamamoto; Y Kuroiwa; Tsuyoshi Yokoi
Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
Clinical pharmacology and therapeutics 2000;67(1):57-69.
2000: Hiroshi Yamazaki; M Suzuki; Kazuhiro Tane; Noriaki Shimada; Miki Nakajima; Tsuyoshi Yokoi
In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Xenobiotica; the fate of foreign compounds in biological systems 2000;30(1):61-70.
1999: Miki Nakajima; M Suzuki; R Yamaji; H Takashina; Noriaki Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
Xenobiotica; the fate of foreign compounds in biological systems 1999;29(12):1191-202.
1999: Miki Nakajima; Sumika Nakamura; Shogo Tokudome; Noriaki Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(12):1381-91.
1999: Hiroshi Yamazaki; Ayaka Shibata; M Suzuki; Miki Nakajima; Noriaki Shimada; F Peter Guengerich; Tsuyoshi Yokoi
Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(11):1260-6.
1999: Miki Nakajima; K Kobayashi; K Oshima; Noriaki Shimada; Shogo Tokudome; K Chiba; Tsuyoshi Yokoi
Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Xenobiotica; the fate of foreign compounds in biological systems 1999;29(9):885-98.
1999: Hiroshi Yamazaki; Miki Nakajima; M Nakamura; Satoru Asahi; Noriaki Shimada; E M Gillam; F Peter Guengerich; Tsutomu Shimada; Tsuyoshi Yokoi
Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(9):999-1004.
1999: Miki Nakajima; K Ohyama; Sumika Nakamura; Noriaki Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(7):792-7.
1994: Miki Nakajima; Tsuyoshi Yokoi; M Mizutani; S Shin; F F Kadlubar; Tetsuya Kamataki
Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1994;3(5):413-21.